ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

CCOP Reponses So Far Indicates application To Total 150-200

August 27, 1982

ASCO Advises KRAS Testing In Patients With Metastatic Colorectal Cancer

January 30, 2009

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

December 31, 2010

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Clearinghouse Exec. Secty, Says It Has Failed in Its Objectives, Recommends It Be Dropped

January 13, 1978

Support Available For Studies Abroad

August 12, 1983